Human Genome Sciences, Inc. (HGSI) Cash Flow Statement

Click line-items for a historical chart and %

Net income (loss)	-186.3M
Stock-based compensation expense	21.37M
Depreciation and amortization	12.24M
Amortization of debt discount	14.75M
Charge for impaired investment	0
Facility-related exit credits	0
Accrued interest on short-term investments, marketable securities and restricted investments	-201K
Non-cash expenses and other	1.44M
Accounts receivable	-3.57M
Collaboration receivables
Inventory	-4.6M
Prepaid expenses and other assets	-1.38M
Accounts payable and accrued expenses	1.83M
Accrued payroll and related taxes	-5.13M
Collaboration payable	3.68M
Deferred revenues	162K
Accrued exit expenses
Other liabilities	7.64M
Net cash used in operating activities	-130.52M
Purchase of short-term investments and marketable securities
Proceeds from sale and maturities of short-term investments and marketable securities
Capital expenditures - property, plant, and equipment	-5.25M
Release of restricted investments
Net cash provided by (used in) investing activities	71.62M
Purchase of restricted investments	-165.24M
Proceeds from sale and maturities of restricted investments	164.56M
Proceeds from issuance of common stock	7.77M
Purchase of treasury stock
Net cash provided by financing activities	6.81M
Net decrease in cash and cash equivalents	-52.09M
Cash and cash equivalents - beginning of period	402.05M
Cash and cash equivalents - end of period	349.96M

Entities mentioned with HGSI

View All Entities